Interestingly, when survival time exceeds 115 months, the survival rate of PCa patients with high SLC17A9 expression and the rate of PCa patients with high LINC01679 expression are both significantly higher than that of PCa patients with low SLC17A9 expression and PCa patients with low LINC01679 expression. This evidence concerns the gene SLC17A9 and posterior cortical atrophy.